WO2001047928A3 - Imidazo 1,3,5 triazinone und ihre verwendung - Google Patents

Imidazo 1,3,5 triazinone und ihre verwendung Download PDF

Info

Publication number
WO2001047928A3
WO2001047928A3 PCT/EP2000/012597 EP0012597W WO0147928A3 WO 2001047928 A3 WO2001047928 A3 WO 2001047928A3 EP 0012597 W EP0012597 W EP 0012597W WO 0147928 A3 WO0147928 A3 WO 0147928A3
Authority
WO
WIPO (PCT)
Prior art keywords
triazinones
imidazo
metabolising
phosphodiesterases
medicaments
Prior art date
Application number
PCT/EP2000/012597
Other languages
English (en)
French (fr)
Other versions
WO2001047928A2 (de
Inventor
Ulrich Niewoehner
Helmut Haning
Thomas Lampe
Mazen Es-Sayed
Gunter Schmidt
Erwin Bischoff
Klaus Dembowsky
Elisabeth Perzborn
Karl-Heinz Schlemmer
Original Assignee
Bayer Ag
Ulrich Niewoehner
Helmut Haning
Thomas Lampe
Es Sayed Mazen
Gunter Schmidt
Erwin Bischoff
Klaus Dembowsky
Elisabeth Perzborn
Schlemmer Karl Heinz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999162928 external-priority patent/DE19962928A1/de
Priority claimed from DE10003323A external-priority patent/DE10003323A1/de
Priority to IL15002200A priority Critical patent/IL150022A0/xx
Priority to JP2001549398A priority patent/JP2003519150A/ja
Priority to KR1020027008156A priority patent/KR20020062770A/ko
Priority to PL00356848A priority patent/PL356848A1/xx
Priority to CA002395548A priority patent/CA2395548A1/en
Priority to EP00993611A priority patent/EP1244673A2/de
Application filed by Bayer Ag, Ulrich Niewoehner, Helmut Haning, Thomas Lampe, Es Sayed Mazen, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Schlemmer Karl Heinz filed Critical Bayer Ag
Priority to US10/168,194 priority patent/US6803365B2/en
Priority to MXPA02006240A priority patent/MXPA02006240A/es
Priority to BR0017043-7A priority patent/BR0017043A/pt
Priority to AU28420/01A priority patent/AU781028B2/en
Publication of WO2001047928A2 publication Critical patent/WO2001047928A2/de
Publication of WO2001047928A3 publication Critical patent/WO2001047928A3/de
Priority to US10/892,984 priority patent/US7091203B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Es werden neue Imidazo[1,3,5]triazinone der allgemeinen Formel (I), Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel, insbesondere als Inhibitoren cGMP-metabolisierender Phosphodiesterasen, beschrieben.
PCT/EP2000/012597 1999-12-24 2000-12-12 Imidazo 1,3,5 triazinone und ihre verwendung WO2001047928A2 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR0017043-7A BR0017043A (pt) 1999-12-24 2000-12-12 Imidazo[1,3,5]triazinonas e sua aplicação
AU28420/01A AU781028B2 (en) 1999-12-24 2000-12-12 Imidazo (1,3,5) triazinones and the use thereof
US10/168,194 US6803365B2 (en) 1999-12-24 2000-12-12 Imidazo[1,3,5]triazinones and the use thereof
KR1020027008156A KR20020062770A (ko) 1999-12-24 2000-12-12 이미다조 1,3,5 트리아지논 및 그의 용도
PL00356848A PL356848A1 (en) 1999-12-24 2000-12-12 Novel imidazo[1,3,5]triazinones and the use thereof
CA002395548A CA2395548A1 (en) 1999-12-24 2000-12-12 Imidazo 1,3,5 triazinones and the use thereof
EP00993611A EP1244673A2 (de) 1999-12-24 2000-12-12 Imidazo[1,3,5]triazinone und ihre verwendung
IL15002200A IL150022A0 (en) 1999-12-24 2000-12-12 Imidazo [1,3,5] triazinones and the use thereof
JP2001549398A JP2003519150A (ja) 1999-12-24 2000-12-12 新規なイミダゾ［１，３，５］トリアジノン類及びその使用
MXPA02006240A MXPA02006240A (es) 1999-12-24 2000-12-12 Nuevas imidazo[1,3,5,) triazinonas y su uso.
US10/892,984 US7091203B2 (en) 1999-12-24 2004-07-15 Imidazo[1,3,5]triazinones and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1999162928 DE19962928A1 (de) 1999-12-24 1999-12-24 Neue Imidazo[1,3,5]triazinone und ihre Verwendung
DE19962928.5 1999-12-24
DE10003323A DE10003323A1 (de) 2000-01-27 2000-01-27 Neue Imidazo[1,3,5[triazinone und ihre Verwendung
DE10003323.7 2000-01-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10168194 A-371-Of-International 2000-12-12
US10/892,984 Continuation US7091203B2 (en) 1999-12-24 2004-07-15 Imidazo[1,3,5]triazinones and their use

Publications (2)

Publication Number Publication Date
WO2001047928A2 WO2001047928A2 (de) 2001-07-05
WO2001047928A3 true WO2001047928A3 (de) 2002-05-16

Family

ID=26004043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012597 WO2001047928A2 (de) 1999-12-24 2000-12-12 Imidazo 1,3,5 triazinone und ihre verwendung

Country Status (13)

Country Link
US (2) US6803365B2 (de)
EP (1) EP1244673A2 (de)
JP (1) JP2003519150A (de)
KR (1) KR20020062770A (de)
CN (1) CN1434825A (de)
AU (1) AU781028B2 (de)
BR (1) BR0017043A (de)
CA (1) CA2395548A1 (de)
IL (1) IL150022A0 (de)
MX (1) MXPA02006240A (de)
PL (1) PL356848A1 (de)
TR (1) TR200201638T2 (de)
WO (1) WO2001047928A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287161B6 (sk) * 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
BR0017043A (pt) * 1999-12-24 2003-01-07 Bayer Ag Imidazo[1,3,5]triazinonas e sua aplicação
WO2002009713A2 (de) * 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
MXPA03010119A (es) * 2001-05-09 2005-03-07 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas 2-fenilo sustituidas.
GB0126417D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Crystal structure
DK1478339T3 (da) * 2002-02-22 2008-08-25 Schering Corp Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
DE10224462A1 (de) * 2002-06-03 2003-12-11 Bayer Ag Verwendung von cGMP stimulierenden Verbindungen
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CN1548438A (zh) * 2003-05-16 2004-11-24 烟台开发区北方药物研究所 2-取代苯基-6,8-二烃基-3H-咪唑[1,5α][1,3,5]三嗪-4-酮衍生物,其制备方法及其药物用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
CA2544350A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
CN101287468A (zh) * 2005-02-18 2008-10-15 表面线段公司 制备包含官能性残基或基团的药动学改善的化合物的方法以及包含所述化合物的药用组合物
EP1850853A4 (de) * 2005-02-18 2011-09-07 Surface Logix Inc Pharmakokinetisch verbesserte verbindungen
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
AU2007217965A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US7838550B2 (en) * 2006-02-17 2010-11-23 Wyeth Llc Selective N-sulfonylation of 2-amino fluoro- and trifluoroalkyl substituted alcohols
EP2040698A4 (de) * 2006-07-14 2011-08-10 Shionogi & Co Oximverbindungen und ihre verwendung
KR20090042863A (ko) 2006-08-24 2009-04-30 서피스 로직스, 인크. 약물동력학적으로 향상된 화합물
TW200845962A (en) * 2007-05-08 2008-12-01 Schering Corp Methods of treatment using intravenous formulations comprising temozolomide
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113461694A (zh) * 2021-08-05 2021-10-01 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482941A (en) * 1991-12-11 1996-01-09 Pfizer Inc. Quinazolinone antianginal agents
US5591742A (en) * 1992-08-28 1997-01-07 Pfizer Inc. Pyridopyrimidinone antianginal agents
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
EP0951908A2 (de) * 1998-02-23 1999-10-27 Pfizer Limited Methoden zur Behandlung von Rückenmarkverletzungensbedingter Impotenz

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
ZA969888B (en) 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
BR0017043A (pt) * 1999-12-24 2003-01-07 Bayer Ag Imidazo[1,3,5]triazinonas e sua aplicação

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482941A (en) * 1991-12-11 1996-01-09 Pfizer Inc. Quinazolinone antianginal agents
US5591742A (en) * 1992-08-28 1997-01-07 Pfizer Inc. Pyridopyrimidinone antianginal agents
WO1998049166A1 (en) * 1997-04-25 1998-11-05 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
EP0951908A2 (de) * 1998-02-23 1999-10-27 Pfizer Limited Methoden zur Behandlung von Rückenmarkverletzungensbedingter Impotenz

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
B GOLANKIEWICZ ET AL, J. CHEM. RES., SYNOP., no. 3, 1994, pages 96 - 7, XP000926544 *
B GOLANKIEWICZ ET AL, JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 18, 1995, pages 3558 - 65, XP001010256 *
B GOLANKIEWICZ ET AL, JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, pages 624, XP000926539 *
B GOLANKIEWICZ ET AL, JOURNAL OF ORGANIC CHEMISTRY, vol. 44, no. 10, 1979, pages 1740 - 2, XP000926549 *
B GOLANKIEWICZ ET AL, NUCLEOSIDES & NUCLEOTIDES, vol. 6, no. 4, 1987, pages 663 - 78, XP000926545 *
J B HOLTWICK ET AL, JOURNAL OF ORGANIC CHEMISTRY, vol. 44, no. 22, 1979, pages 3835 - 9, XP000926548 *
J B HOLTWICK ET AL, JOURNAL OF ORGANIC CHEMISTRY, vol. 46, no. 18, 1981, pages 3681 - 5, XP000926547 *
YONGFENG WANG ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 2, 1996, pages 185 - 8, XP000926543 *
YONGFENG WANG ET AL, JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANS. 1, no. 10, 1998, pages 1669 - 75, XP000926542 *

Also Published As

Publication number Publication date
TR200201638T2 (tr) 2002-11-21
MXPA02006240A (es) 2003-01-28
US7091203B2 (en) 2006-08-15
AU781028B2 (en) 2005-04-28
AU2842001A (en) 2001-07-09
BR0017043A (pt) 2003-01-07
IL150022A0 (en) 2002-12-01
KR20020062770A (ko) 2002-07-29
WO2001047928A2 (de) 2001-07-05
CN1434825A (zh) 2003-08-06
US20030195210A1 (en) 2003-10-16
PL356848A1 (en) 2004-07-12
CA2395548A1 (en) 2001-07-05
US20050043303A1 (en) 2005-02-24
EP1244673A2 (de) 2002-10-02
JP2003519150A (ja) 2003-06-17
US6803365B2 (en) 2004-10-12

Similar Documents

Publication Publication Date Title
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
WO1999054326A8 (de) Dihydropyrimidine
CA2334773A1 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
WO2001072728A3 (en) Novel piperazine derivatives
WO2002032898A3 (de) Neue anticholinergika, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
WO2002005782A3 (de) Stabile salze von o-acetylsalicylsäure mit basischen aminosäuren
CA2396720A1 (en) Thiazolyl amide derivatives
CA2419314A1 (en) Preparation of risperidone
WO2002102787A3 (en) Novel sulfonic acid derivatives
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
WO2001058875A3 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
WO2002080914A3 (de) VERWENDUNG VON SUBSTITUIERTEN IMIDAZO[1,2-a]-PYRIDINVERBINDUNGEN ALS ARZNEIMITTEL
WO2001002350A3 (de) Neue amino- und amidosulfonamide als antivirale mittel
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
WO2000046210A3 (en) New process for preparing pesticidal intermediates
WO2002014313A3 (de) Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
AU2001258200A1 (en) Synthetic derivatives of lunularic acid, medicaments containing said compounds, method for producing the lunularic acid derivatives and the use thereof
WO2002080911A3 (de) Verwendung substituierter imidazo[1,2-a]-pyridin-3-yl-amid- und imidazo[1,2-a]-pyridin-3-yl-aminverbindungen als arzneimittel zur behandlung von neurodegenerativen erkrankungen
ATE307809T1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
CA2366600A1 (en) A process for the preparation of 1,4,7,10-tetraazacyclododecane

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000993611

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/04457

Country of ref document: ZA

Ref document number: 150022

Country of ref document: IL

Ref document number: 200204457

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 28420/01

Country of ref document: AU

Ref document number: IN/PCT/2002/00821/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006240

Country of ref document: MX

Ref document number: 2395548

Country of ref document: CA

Ref document number: 2002/01638

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020027008156

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 549398

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027008156

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008189692

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000993611

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10168194

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 28420/01

Country of ref document: AU